Lv613
1940 积分 2021-12-16 加入
The real experience of reporting electronic patient-reported outcomes in patients with inflammatory arthritis and factors influencing participation: a scoping review
3小时前
已完结
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
1天前
已完结
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
1天前
已完结
Population Pharmacokinetics of Xeligekimab: An Anti‐IL‐17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis
1天前
已关闭
Population Pharmacokinetics of Xeligekimab: An Anti‐IL‐17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis
1天前
已完结
Vunakizumab: First Approval
10天前
已完结
Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study
1个月前
已完结
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
2个月前
已完结
皖公网安备34019202002308
